Broadened T-cell Repertoire Diversity in ivIg-treated SLE Patients is Also Related to the Individual Status of Regulatory T-cells by Costa, Nuno et al.
 1 
Broadened T-cell repertoire diversity in ivIg-treated SLE patients is also related to 
the individual status of regulatory T-cells 
Nuno Costa1*, Ana E. Pires2,13,14*, Ana M. Gabriel1*, Luiz F. Goulart1, Clara Pereira1,3, 
Bárbara Leal3, Ana C. Queiros2, Wahiba Chaara4,5,6, Maria F. Moraes-Fontes1,8, Carlos 
Vasconcelos7, Carlos Ferreira8, Jorge Martins9, Marina Bastos10, Maria J. Santos11, 
Maria A. Pereira12, Berta Martins3, Margarida Lima7, Cristina João2, Adrien Six4,5, 
Jocelyne Demengeot1, Constantin Fesel1 
1Instituto Gulbenkian de Ciência, Apartado 14, P-2781-901 Oeiras, Portugal 
2Centro de Estudos de Doenças Crónicas Faculdade de Ciências Médicas, Universidade 
Nova de Lisboa (CEDOC-FCM-UNL), Rua Prof. Lima Basto, 1099-023 Lisboa, 
Portugal 
3Instituto de Ciências Biomédicas Abel Salazar, Largo Prof. Abel Salazar 2, 4099-003 
Porto, Portugal 
4UPMC Univ Paris 06, UMR 7211, F-75013 Paris, France 
5CNRS Centre National de la Recherche Scientifique, UMR 7211, F-75013 Paris, 
France 
6AP-HP, Pitié Salpêtrière Hospital, Service de Biothérapie, F-75013 Paris, France 
7Hospital de Santo António, Largo Prof. Abel Salazar 2, 4099-003 Porto, Portugal 
8Hospital de Santa Maria, Av. Prof. Egas Moniz, 1649-035 Lisboa, Portugal 
9Hospital dos Marmeleiros, Estrada dos Marmeleiros Monte, 9054-535 Funchal, 
Portugal 
10Hospital São Teotónio, Av. do Rei D. Duarte, 3504-509 Viseu, Portugal 
11Hospital Garcia de Orta, Av. Torrado da Silva, 2801-951 Almada, Portugal 
12Hospital de Faro, Rua Leão Penedo, 8000-386 Faro, Portugal 
13Grupo de Biologia Molecular, Instituto Nacional de Investigação Agrária e 
Veterinária, I.P., Estr. do Paço do Lumiar, 22, Ed. S, 1649-038 Lisboa, Portugal 
14Centro de Biologia Ambiental, Faculdade de Ciências, Universidade de Lisboa, 
Portugal 
*These authors contributed equally to the work 
Corresponding author: Constantin Fesel, Instituto Gulbenkian de Ciência, Apartado 14, 
P-2781-901 Oeiras, Portugal. Tel. +351 21 4407900, Fax +351 21 4407970, Email 
cfesel@igc.gulbenkian.pt 
 
 2 
Abstract 
Purpose: Intravenous IgG (ivIg) is a therapeutic alternative for lupus erythematosus, the 
mechanism of which remains to be fully understood. Here we investigated whether ivIg 
affects two established sub-phenotypes of SLE, namely relative oligoclonality of 
circulating T-cells and reduced activity of CD4+Foxp3+ regulatory T-cells (Tregs) 
reflected by lower CD25 surface density. 
Methods: We conducted a longitudinal study of 15 lupus patients (14 with SLE and one 
with discoid LE) treated with ivIg in cycles of 2-6 consecutive monthly infusions. 
Among these 15 patients, 10 responded to ivIg therapy with clear clinical improvement. 
We characterized Tregs and determined TCR spectratypes of four Vβ families with 
reported oligoclonality. Cell counts, cytometry and TCR spectratypes were obtained 
from peripheral blood at various time points before, during and after ivIg treatment. T-
cell oligoclonality was assessed as Vβ-familywise repertoire perturbation, calculated for 
each patient in respect to an individual reference profile averaged over all available time 
points. 
Results: For 11 out of 15 patients, average Vβ1/Vβ2/Vβ11/Vβ14 repertoires were less 
perturbed under than outside ivIg therapy. The four exceptions with relatively increased 
average perturbation during ivIg therapy included three patients who failed to respond 
clinically to an ivIg therapy cycle. Patients' Treg CD25 surface density (cytometric 
MFI) was clearly reduced when compared to healthy controls, but not obviously 
influenced by ivIg. However, patients' average Treg CD25 MFI was found negatively 
correlated with both Vβ11 and Vβ14 perturbations measured under ivIg therapy. 
Conclusions: This indicates a role of active Tregs in the therapeutic effect of ivIg. 
 
Keywords: Systemic Lupus Erythematosus, Autoimmunity, Intravenous IgG, TCR 
spectratypes, Regulatory T-cells, CD25 
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Introduction 
High-dose intravenous infusion therapy with natural IgG pooled from a large number of 
donors, termed intravenous immunoglobulin (ivIg), is an effective anti-inflammatory 
therapy in a variety of autoimmune diseases (1). In patients with Systemic Lupus 
Erythematosus (SLE) and other forms of lupus, ivIg is not a standard therapy but used 
as an alternative and complementary therapy that is safe and beneficial for the large 
majority of treated patients (2, 3). The involved mechanisms, however, are not fully 
identified. Best documented are Fc receptor-mediated effects (4), particularly involving 
the inhibitory FcγRIIb (5), but also other mechanisms are likely involved that depend on 
Fab specificities and idiotypes (1). IvIg can reportedly stimulate T-cells (6-8), and 
particularly the stimulation of Foxp3+ regulatory T-cells (Tregs), directly demonstrated 
in cell culture (9), is most likely involved in the beneficial ivIg effects to autoimmunity 
(10-13). Tregs, which can inhibit the proliferation of activated conventional T-cells and 
are essential for their regulation (14), are in fact specifically altered in SLE (15), and 
particularly their reduced surface expression of the high-affinity IL-2 receptor (CD25), 
likely resulting in impaired functionality (16-18), has been convincingly and repeatedly 
reported. The possible relevance of Tregs for ivIg therapy, however, has not been 
systematically investigated so far. 
Impaired Treg function leads to deregulated clonal expansion of T-cells and repertoire 
oligoclonality in vivo, as it is most evident in primary Treg deficiencies of mice (19) 
and humans (20). T-cell oligoclonality can be assessed by studying the diversity of T-
cell receptor (TCR) rearrangements, either by assessing the relative usage of TCR Vα 
or Vβ families, by direct sequencing, or most commonly by spectratyping, i.e. the 
analysis of size diversity in the CDR3 region that originates from random 
recombination and imprecise joining of TCR gene segments (21). Such oligoclonality 
was indeed regularly found in various autoimmune conditions (22-27) and is commonly 
interpreted as the result of selectively expanded T-cell clones. In SLE, oligoclonal T-
cell expansions were found to characterize both the chronic disease per se (28-32) and 
kidney manifestation (33), although it is not known whether expanded clones were 
directly pathogenic. Further evidence indicated that these oligoclonal expansions were 
highly instable during active disease, while not in inactive SLE (32). In order to study 
TCR diversity under ivIg therapy, here we followed for the first time the longitudinal 
development of TCR spectratypes in individual patients before, during and after ivIg 
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therapy, combined with the assessment of Treg properties. We studied 14 SLE patients 
and one patient with discoid lupus treated with 2-12 consecutive ivIg infusions. 
Analyzing TCR spectratypes of four Vβ families with alterations in SLE, reported (29), 
in respect to their time-dependent deviation from individual average profiles, we found 
that (a) TCR repertoire perturbation, here indicating temporary oligoclonal expansions, 
was significantly reduced under ivIg therapy when compared with samples from the 
same patient taken before or after ivIg therapy, and that (b) the individual repertoire 
perturbation under ivIg was in two out of four studied Vβ families strongly correlated 
with the individual activity of Foxp3+ Tregs reflected by their average surface CD25 
expression. 
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Methods 
Patients and sampling 
We studied a total of 15 patients (14 with SLE, 1 with discoid LE) treated with monthly 
infusions of ivIg with total doses ranging between 400 mg and 2 g per kg body weight, 
and 16 healthy blood donors as controls. The response to ivIg was assessed in terms of 
SLEDAI changes and clinical evaluation by the physicians who performed the 
treatment, and the study was entirely observational and open-label. IvIg was generally 
added to individually stable base therapies (see Table 1). Approval was obtained from 
the Ethics Committee of the Portuguese Lupus Patients Association, and all collections 
were performed after written informed consent. An overview of the patient 
characteristics and the number of followup samples taken from each patient is given in 
Table 1. Although patients had disease with different degrees of clinical severity, only 
one (F6) had active renal involvement but with creatinine levels that always remained 
normal. Peripheral blood (30 mL per sample) was regularly drawn before each monthly 
ivIg infusion. In some instances, particularly at the time when a patient received the first 
ivIg infusion, additional samples were taken at the end of an ivIg infusion, i.e., 1-5 days 
after the initial sampling. 
Flow cytometry 
Peripheral blood mononuclear cells (PBMC) were isolated using Vacutainer CPT 
tubes (Becton Dickinson). 1x106 PBMC were then washed twice in PBS containing 2% 
fetal calf serum, and incubated for 30 min on ice with FITC-anti-CD4 (ebioscience, ref. 
#11-0049-73), PE/Cy5-anti-CD45RO (Becton Dickinson, ref. #555494) and PE-anti-
CD25 (Becton Dickinson, ref. #341011). For intracellular staining, cells were washed 
again, fixed and permeabilized using a fix/perm kit (ebioscience) according to the 
manufacturer's instructions, and stained for intracellular Foxp3 with APC-anti-FoxP3 
(ebioscience, ref. #45-4776-73). Fluorescence was assessed using a FACScalibur flow 
cytometer, using unchanged cytometer settings and the CellQuest software. For PE-
anti-CD25 staining, also the median fluorescence intensity (MFI) was quantified and 
analyzed in terms of its log transformation (log-MFI). However, not all samples from all 
patients were stained for CD25, and individual average log-MFIs were calculated from 
those samples of a given patient where CD25 staining was available. 
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TCR CDR3 spectratyping 
From 5 million PBMC, total RNA was isolated using a commercial kit (E.Z.N.A.® 
Blood RNA Kits). From an average of 150 ng total RNA per sample, cDNA was 
synthesized by the SuperScriptIII First-Strand Synthesis System for RT-PCR 
(Invitrogen). TCR BV(Vβ)-specific spectratypes were then obtained for the TCR CDR3 
length distributions of the BV1, BV2, BV11 and BV14 families by the method 
described by Pannetier et al.  (21). Briefly, synthesized cDNA was used to amplify each 
BV family separately. The 25µL PCR mixture contained 0.2mM dNTP (Promega), 
2mM MgCl2 (Promega), 0.5µM TCRBV-specific forward primer, 0.2µM TCRBC 
reverse primer (5'-CGGGCTGCTCCTTGAGGGGCTGCG-3') and 0.8U Taq 
polymerase (Promega). Amplification reactions were performed in a MJ Research 
PTC100 thermocycler with an initial denaturation step of 94ºC for 4 minutes, followed 
by 40 cycles of 94 ºC for 45 seconds, 60 ºC for 45 seconds and 72ºC for one minute. A 
final extension step at 72 ºC for 10 minutes was performed. The forward primer 
sequences were as follows: 
hTCRBV1 (5’-CCGCACAACAGTTCCCTGACTTGC-3’); 
hTCRBV2 (5’-ACATACGAGCAAGGCGTCGA-3’); 
hTCRBV11 (5’-GTCAACAGTCTCCAGAATAAGG-3’); 
hTCRBV14 (5´-GGGCTGGGCTTAAGGCAGATCTAC-3’).  
The achieved amplicons were then used in a run-off reaction with the labelled reverse 
primer hTCRBC-FAM (FAM-5'-ACACAGCGACCTCGGGTGGG-3') in order to label 
PCR products, using an initial denaturation step of 94ºC for 4 minutes followed by 5 
cycles of 94 ºC for 45 seconds, 60 ºC for 45 seconds and 72ºC for one minute. For the 
precise determination of fragment sizes, 2µL of the run-off products in the presence of 
the fluorescent size marker ABI Genescan 500 ROX were separated on an automated 
ABI 3130XL multicapillary gel system (Perkin Elmer-Applied Biosystems). 
Spectratype data were extracted using GeneMapper (v. 3.7, from Applied Biosystems, 
CA, USA). Briefly, the software program identified each histogram peak by its PCR-
size length and determined the area under each peak.  
Spectratype analysis  
Spectratypes of the CDR3 region from an ideal naive repertoire follow an approximate 
Gaussian distribution containing eight or more peaks (34). Skewed CDR3 Vβ profiles 
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can be detected as perturbation of this distribution. Accordingly, we analyzed 
spectratype data with the ISEApeaks® software package (34, 35). For each Vβ(BV)-
familywise CDR3 length profile, the percentage of each peak was quantified by 
dividing its area by the total area of all detectable peaks within the profile. For each BV 
family analyzed, individual reference profiles were furthermore computed as the 
average CDR3 peak distribution of all samples drawn from each respective patient 
undergoing ivIg therapy. Then, the generalized Hamming distance between the peak 
profile of each single sample and that of the reference profile for the respective patient 
was calculated for each BV. This distance was used as perturbation index (36, 37) 
ranging from 0% (identical profiles) to 100% (complete divergence). For a few samples 
without any detectable amplification for one but successful amplification of other BV 
families, perturbation was considered 100% for the non-amplifying family if other 
samples of the same patient showed amplification in this family. A few other samples 
that showed low-grade but visible amplification not reaching the detection threshold, as 
well as all BV1 profiles from three patients where regularly no amplification was 
detected, were excluded from the analysis. 
For individual comparisons of profiles under and outside ivIg therapy, perturbation 
indices were averaged over the detectable BV families and the respective samples of a 
given patient either under or outside ivIg treatment. Samples were considered under ivIg 
if taken at least 25 days after a respective first ivIg infusion. Samples drawn either 
before the first ivIg infusion of a therapy cycle or at least 45 days after a respective last 
ivIg infusion were considered outside ivIg treatment. Some samples, particularly those 
collected immediately after the end of the first ivIg infusion received by a patient, were 
neither considered under nor outside ivIg treatment, but only taken into account to 
calculate the individual reference profile. Generalized paired t-tests, according to 
Rosner's adapted statistic design (38) for the case where paired comparisons consist of 
variable numbers of multiple observations of each type as it is the case in our study, 
were calculated for perturbation averages under versus outside ivIg treatment either 
over the pairings available for a respective BV (12 for BV1 that was undetectable in 
three patients, and 15 for BV2, BV11 and BV14), or over all 57 available patient- and 
BV-familywise pairings jointly. The likelihood optimization necessary for Rosner's 
generalized paired t-test was performed by several consecutive runs of the algorithm 
'Amoeba' (39) using the software IgorPro (WaveMetrics). Otherwise we preferentially 
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used distribution-independent statistical tests: the Mann-Whitney test for group 
comparisons, and Spearman rank correlation for correlations, which were calculated 
with accordingly adapted macros on the software IgorPro. Weighted least squares 
regression was calculated with the lm function implemented in the R statistics package 
(40), using the square root of the sample number considered per patient as weighting 
factor. P-values below 0.05 were generally considered significant. 
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Results 
Evolution of TCR CDR3 profiles during ivIg therapy 
Immunoscope spectratyping (21) (see methods) was used to examine the size 
distribution of TCR CDR3 Vβ chain rearrangements in four Vβ families in 15 patients 
before, during and after ivIg therapy that included six consecutive monthly infusions at 
dosages indicated for autoimmune disorders (see methods). We selected the Vβ1, Vβ2, 
Vβ11 and Vβ14 families for our study since they showed the best published evidence 
for specific alterations and shared oligoclonality in SLE patients (29). Table 1 gives an 
overview of our studied patients: they were treated with ivIg due to systemic or 
cutaneous flares, most of them in parallel with corticosteroids and/or cytostatics, and 
mostly responded well to ivIg. CDR3 size profiles from one exemplary patient are 
shown in Fig. 1, and analogous profiles for a second patient can be seen in the 
supplementary figure S1. In Fig. 1, before ivIg therapy and immediately after the first 
infusion very few peaks can be seen in the profiles of all four Vβ families, indicating 
high repertoire oligoclonality and severe diversity constraint (Fig. 1, days 0 and 4). 
During ivIg therapy, it is evident that the rearrangements of all four Vβ families evolved 
toward a more diverse repertoire characterized by approximately Gaussian-distributed 
sizes. Thus, the expanded clones that had predominated before the initiation of ivIg 
infusion (pathogenic or not) either disappeared or were substantially reduced in 
frequency in all four Vβ families studied during ivIg therapy. Diversified profiles under 
ivIg were overall individually stable, although they did not always converge to ideal 
Gaussian distributions, as it can be seen for the Vβ1 family in Fig. 1. Such small but 
stable deviations, also seen in other patients, likely reflected individual particularities as 
they have also been reported in healthy control subjects (29). Since we collected 
consecutive samples from our patients, we defined individual reference profiles by the 
average of all profiles obtained from each respective patient and Vβ family (instead of 
an average control group reference profile as it is usually done when repeated 
measurement are not available). As in previous studies, relative oligoclonality was then 
described by the perturbation index (36, 37) of each sample and Vβ family, here 
reflecting the deviation of the spectratype assessed at each time point from the average 
profile calculated for the same patient: the more a profile deviated from this individual 
average at a given time point, the more perturbed we considered the TCR repertoire at 
that time point. 
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Reduced TCR repertoire perturbation under ivIg therapy 
In order to address the question whether ivIg therapy had an effect on TCR repertoire 
diversity, we compared, for each patient, average perturbations of all detectable Vβ 
families under and outside ivIg treatment (the latter including time points before and 
after the treatment period, also see methods). For 11 of the 15 patients studied, average 
perturbations were lower under ivIg treatment. Nine of these 11 patients had responded 
to ivIg therapy with clinical improvement. The four exceptions (F2, F4, P150, FA1), in 
contrast, where the average perturbation was relatively increased during ivIg therapy, 
included three patients who failed to respond clinically to at least one therapy cycle (F2, 
F4, P150). The reduced perturbation under ivIg can also be seen for most of the 
respective pairings for individual Vβ families (Fig. 2). 
Accordingly, we tested whether the reduced perturbation under ivIg therapy was 
statistically significant when considering all patients and all Vβ-families together, by 
paired comparisons of perturbation averages under versus outside ivIg treatment. For 
this purpose we used the generalization of the paired t-test for multiple comparisons per 
pairing (38), which also takes the numbers of each observation type per pairing into 
account. Calculated on all 4x15-3 patient- and Vβ-familywise pairings (see methods), 
we found that the difference was clearly significant (P=0.0001), and also when 
calculated for each individual Vβ separately, it was significant for three out of four (Vβ 
1: P=0.02; Vβ 2: P=0.049; Vβ 11: P=0.03). This is further illustrated by Fig. 3, which 
shows the individual development of all four Vβ-family perturbation scores assessed in 
six selected patients. Among them, F3, P97, F8 and LI1 (Fig. 3, upper part) represent 
patients with reduced perturbation under ivIg who also responded successfully to ivIg 
therapy, while F4 and F2 (Fig. 3, lower part) showed no reduced perturbation and failed 
to improve clinically during an ivIg therapy cycle. Although a reduction in the 
perturbation during treatment periods (arrows in Fig. 3) is noticeable in the first group 
of patients, the dynamics of TCR repertoire perturbation differed between individual 
patients. While F3 almost immediately diminished perturbation in response to ivIg 
therapy, F8 reached clearly lower levels only at the end of ivIg therapy. P97, in contrast, 
showed no visibly increased perturbation before ivIg therapy and displayed little change 
during therapy, while the perturbation rose in all four Vβ families at the end of the ivIg 
treatment period. LI1 had two consecutive ivIg infusion cycles (arrows) (for full CDR3 
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size profiles of this patient, see supplementary figure S1). After a first six-month 
therapy cycle with little visible change in the TCR repertoire, the patient suffered a 
clinical relapse before receiving a second cycle of ivIg infusions. It is apparent from 
Fig. 3 that this relapse (between the arrows) was accompanied by high perturbation in 
all four Vβ families, which, however, rapidly normalized when the patient resumed ivIg 
therapy. In the group of patients without clinical improvement, F4 never reduced TCR 
repertoire perturbation during the ivIg therapy in any family. F2 received two 
consecutive therapy cycles, motivated as for LI1 by a disease flare that followed the 
initially successful first cycle (full arrow). When ivIg therapy was resumed, however, it 
failed to improve the clinical symptoms of the patient and was therefore interrupted 
after three monthly infusions (dashed arrow). In contrast to LI1, F2 showed no 
reduction of TCR repertoire perturbation during ivIg treatment. 
While reduced repertoire perturbation was clearly visible one month after the first ivIg 
infusion, samples that we took occasionally immediately after the first infusion were not 
clearly different from those taken before. A possibly interesting exception was patient 
FA1, where an individual Vβ1 fragment size virtually disappeared immediately after 
two consecutive ivIg infusions, but later reappeared (see supplementary fig. S2). 
Treg CD25 surface density correlates with lower TCR repertoire perturbation 
From the same blood samples used for spectratype analysis, we also stained freshly 
isolated peripheral blood mononuclear cells (PBMC) for flow cytometry analysis in 
order to quantify and characterize CD4+Foxp3+ regulatory T-cells (Tregs). We 
measured frequencies within total CD4+ T-cells and CD25 surface density represented 
by median fluorescence intensity (MFI, see methods), for total CD4+FoxP3+ Tregs and 
three CD4+Foxp3+ subpopulations as defined (41), depicted in Fig. 4: CD45RO+FoxP3hi 
(activated Treg; R6 in Fig. 4), CD45RO+FoxP3lo (supposedly nonsuppressive 'non-
Treg'; R5), and CD45RO-FoxP3lo (naive-like 'resting' Treg; R7). Analyzing all Foxp3+ 
Tregs, we found CD25 MFI, but not Treg/CD4+ frequency, clearly reduced in the 
patients when compared to healthy controls (Fig. 5). However, these parameters were 
not evidently influenced by ivIg since comparisons of Treg frequency or CD25 MFI 
before versus after ivIg were insignificant (not shown, but see supplementary figure S3 
for individual changes in CD25 MFI under ivIg). Still, Treg properties of individual 
patients might influence ivIg effects, and particularly its reduction of TCR repertoire 
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perturbation. What concerns Treg frequencies, we did not find such an influence (Table 
2). Analyzing surface CD25 density, in contrast, we found surprisingly that the patients 
with relatively high Treg average CD25 MFI also had clearly lower TCR perturbations 
under ivIg in two out of four studied Vβ families (Vβ11 and Vβ14). This resulted in 
strong and significant negative correlations that were equally evident in terms of 
distribution-independent Spearman correlation and calculated by weighted least squares 
regression, taking the different sample numbers per patient under ivIg into account 
(Table 2, Fig. 6). Individual differences in Treg CD25 MFI that we found correlated 
with repertoire perturbation under ivIg were themselves clearly not caused neither 
demonstrably influenced by ivIg treatment, but rather largely existed already before ivIg 
initiation and were unrelated to changes under ivIg (supplementary Fig. S3). When 
analyzing Treg subsets analogously, average CD25 densities in both the 
CD45RO+FoxP3hi and CD45RO+FoxP3lo subsets showed similar negative correlations 
with Vβ11 and Vβ14 perturbation. Only in naive/resting CD45RO- Foxp3+ cells, there 
was no correlation detected between CD25 surface density and TCR perturbation, as it 
was also the case for the naïve (CD45RO-) and memory (CD45RO+) subsets of 
conventional CD4+Foxp3- T-helper cells (Table 2). In contrast to Vβ11 and Vβ14, the 
perturbation scored in the Vβ1 and Vβ2 families did not significantly correlate with 
CD25 surface densities. 
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Discussion 
The adaptive immune system with its specific capacity to eliminate pathogens is based 
on antigen-specific B- and T-cells. Although the size of specifically responsive T-cell 
clones can markedly increase upon antigenic stimulation, the number of expanded 
memory cells resulting from such stimulation is normally very limited and preserves an 
overall repertoire of high diversity. However, it has been demonstrated that during acute 
and chronic viral infections the T-cell repertoire can be biased by selective clonal 
expansions (42-45). Particularly in various immunodeficient conditions, the T-cell 
repertoire diversity is reduced, and their repair can be monitored by the assessment of 
TCR diversity, e.g. in immune reconstitution following bone marrow transplantation 
(46-48) and during antiretroviral therapy of HIV infection (36, 49). In these conditions, 
where a small number of clones may expand by homeostatic proliferation and yield 
normal lymphocyte numbers but not a repertoire of normal diversity, the assessment of 
repertoire diversity is of proven relevance.  
Patients with autoimmune disorders also have typical constraints of their lymphocyte 
repertoire with an overrepresentation of expanded clones. Skewed and oligoclonal T-
cell repertoires with persistently expanded clones have been reported in rheumatoid 
arthritis (22, 24), multiple sclerosis (25), psoriasis vulgaris (26), myasthenia gravis (27), 
and Crohn’s disease (23). The presence of these oligoclonal T-cell populations, 
including 'public' clones with identical rearrangements found in different patients, 
supports the notion that antigen-specific T-cell activation is a major pathogenetic 
mechanism of inflammation in these conditions. In patients with HLA-DR4+ 
rheumatoid arthritis, the TCR repertoire of T-cells responding to a major epitope of 
collagen was found restricted to a limited number of rearrangements that were shared 
between patients (50). In the peripheral blood of MS patients, the Vβ5.2 gene family 
was often oligoclonally expanded, while predominant TCR clones were stable over time 
but different from patient to patient (25). Stably expanded T-cell clones were also 
identified in skin lesions of patients with psoriasis vulgaris (26). In human SLE, besides 
the well-documented B-cell oligoclonality (51), also oligoclonal TCR repertoires have 
been repeatedly reported (29-31). Extensive sequencing has furthermore revealed that 
expanded T-cell clones persisted during disease inactivity, but became short-lived and 
highly volatile in periods of active disease (32). 
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Studying the effect of ivIg therapy on TCR repertoires in SLE patients, we have now 
found that their perturbation was relatively reduced under clinically successful ivIg 
therapy, supporting the notion that the beneficial effect of ivIg includes a stabilization 
of diversified TCR repertoires, as we have already described it in other contexts (6, 7). 
This result is principally robust against confounders such as possible intercurrent 
infections, since these could only increase but not reduce the repertoire perturbation. 
Without knowing to which extent expanded clones were pathogenic or not, we found 
that the individual repertoire perturbation under ivIg in two of four Vβ families studied 
(Vβ11 and Vβ14) was strongly correlated with the individual average surface CD25 
density on Foxp3+ Tregs. This is in good agreement with the generally accepted 
evidence that Tregs control the proliferation and clonal expansion of conventional T-
cells (14), and with the notion that CD25 (the IL-2 receptor α chain that enables high-
affinity IL-2 binding) surface density indicates the relative activity of human Tregs. 
This is particularly well supported for SLE, where CD25+ or CD25bright rather than total 
Foxp3+ Tregs were found deficient (15, 52-55), and more recently their reduced CD25 
expression (17, 18) was directly associated to the previously described functional 
deficiency of Foxp3+ Tregs in SLE (16). 
Our finding that repertoire diversity under ivIg treatment was significantly correlated 
with individual Treg surface CD25, thus likely with Treg activity (17, 18), does not 
exclude Treg-independent effects of ivIg that could also inhibit specific clonal 
expansion. However, this result strongly supports the hypothesis that under ivIg therapy 
Tregs substantially contribute to controlling and limiting expanded T-cell clones, likely 
including pathogenic ones, which (although we have no direct evidence for it) raises the 
possibility that also the therapeutic effect of ivIg could in part depend on functionally 
active CD25bright Tregs that are present to different extents in individual patients. The 
alternative explanation, an impact of repertoire diversity on the individual Treg status, 
seems much more farfetched and is particularly difficult to reconcile with the relatively 
rapid changes that we detected over time in the same patients in repertoire diversity but 
not in Treg properties. The third theoretically possible explanation, a correlation of 
secondary effects due to a shared primary effect (ivIg), can be readily excluded since 
CD25 MFI, other than repertoire diversity, did not detectably depend on ivIg treatment 
in our study. The fact that the clinical nonresponders were equally well fitted suggests 
that the putative mechanism that linked active Tregs to repertoire diversity was present 
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also in this group, explainable by the possibility that disease activity was here driven by 
effects other than oligoclonal T-cell expansion that escaped T-cell regulation. It is 
furthermore interesting that the correlations of CD25 MFI with repertoire diversity 
under ivIg were similarly significant in both the CD4+CD45RO+Foxp3bright and 
CD4+CD45RO+Foxp3low Treg subsets. This supports the hypothesis that the latter, at 
least in SLE, represents a true Treg population as suggested (16, 17), and not merely 
activated conventional T-cells with transient low-grade Foxp3 expression (41). We do 
not know, however, if it has an informative value that only Vβ11 and Vβ14 diversity 
was significantly correlated with the expression of CD25 on Tregs. Since correlation 
coefficients with Treg CD25 (Table 2) were throughout negative also for Vβ1 and Vβ2, 
it is well possible that our interpretation principally also applies to them and that the 
different significances were due to sample bias. Still, it is also possible that effector T-
cells bearing Vβ11 and Vβ14 are indeed overrepresented in SLE-associated 
autoimmune reactions and that Tregs accordingly suppressed them more than others. 
In our study we did not find evidence that Treg properties depended on ivIg treatment. 
However, our study is certainly not sufficient to make any conclusion in this respect, 
and a Treg-mediated effect of ivIg has indeed previously been described in experimental 
autoimmune encephalomyelitis in mice (11). Also in human Kawasaki disease, where 
ivIg is an established therapy, its therapeutic effect was recently reported to be 
accompanied by the repair of a Treg deficit (13). Moreover, the study of bone marrow 
reconstitution has suggested an effect of ivIg on T-cell repertoires that included Tregs 
(6-8). In this condition, ivIg generally stimulates T-cells, likely by natural antigenicity 
included in the polyclonal immunoglobulin preparation (56). Indeed, Tregs, known in 
many ways and likely selected to recognize self antigens (57), were recently also found 
to be stimulated by major MHC class II-restricted epitopes in the Fc portion of human 
IgG, accordingly called 'Tregitopes' (10). The fact that we found no difference, both in 
cell number and CD25 expression, in the Treg compartment during ivIg therapy in our 
study, means that effects of ivIg on Tregs here either implied only a small subset of 
Tregs without detectably affecting the overall Treg status, or that other ivIg mechanisms 
played the principal role in the increased diversity of the T-cell repertoire. In the OVA-
specific humoral immune response in mice, ivIg in fact rather interfered with the 
generation of antigen-specific T cells. Further in vitro experiments revealed that the 
effect of IvIg was mediated by APCs, resulting in an inhibition of upstream signals 
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provided by APCs that inhibited T-cell activation, proliferation, and cytokine secretion 
without ivIg directly interacting with T-cells (58). However, additional studies 
addressing the roles of the different effects of ivIg in humans are clearly required. 
 
Conclusions 
Our findings support an influence of Tregs on ivIg effects. This is in agreement with the 
interpretation that ivIg, besides its effects on Fc receptors and circulating antibodies, 
could protect a healthy and diverse T-cell repertoire from destabilizing effects also by 
providing natural antigenic stimuli, with an overall effect of limiting clonal expansion, 
thus 'buffering' natural T-cell repertoires. 
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Figure Legends 
Fig. 1 TCR CDR3 Vβ1, Vβ2, Vβ11 and Vβ14 spectratype profiles of patient F3 before 
and during ivIg therapy. Each column corresponds to the indicated Vβ family. Each row 
corresponds to a time point relative to the first ivIg infusion, expressed in days: D000 is 
the initial sample collected before ivIg treatment. Each panel depicts the distribution of 
amplified CDR3 fragment sizes, with the X axis representing an appropriately defined 
range of sizes for each Vβ family. Each peak represents a defined CDR3 length. The 
number in each panel insert, ranging from 0 to 100, is the perturbation index calculated 
at each time point in respect to patient F3’s average profile for the respective Vβ family. 
 
Fig. 2 Average TCR CDR3 perturbations are decreased in patients successfully treated 
with ivIg. TCR CDR3 perturbation indexes, as shown in Fig. 1 for patient F3, were 
determined for all patients, time points and Vβ families. Average perturbation scores 
were calculated for each patient and Vβ (a) for the time points under ivIg treatment 
(black bars) and (b) for those outside ivIg treatment (grey bars). Patients are indicated 
by their codes on the x axis. Patients who did not respond clinically to a therapy cycle 
are indicated with a star. The number of total samples obtained from each patient is 
annotated in brackets, e.g.: LI1 (20 samples under ivIg + 6 outside ivIg treatment). 
 
Fig. 3 Individual evolutions of TCR CDR3 perturbations in six patients treated with 
ivIg. Each panel represents one patient. The Vβ families are indicated in each panel by 
different line styles: Vβ1 dotted, Vβ2 dashed, Vβ11 solid, Vβ14 dotted and dashed. 
Arrows at the bottom of each panel mark the time periods when the respective patient 
was under ivIg treatment: full arrows indicate treatment cycles with clinical 
improvement, dashed arrows cycles without clinical improvement. 
 
Fig. 4 Representative cytometric profile of Foxp3 and CD45RO staining (gated on 
CD4+ T-cells). Gates R5-R6 indicate the analyzed subpopulations of Foxp3+ T-cells: 
Foxp3lowCD45RO+ (R5, described as nonsuppressive); Foxp3highCD45RO+ (R6, 
activated Tregs); Foxp3+CD45RO- (R7, ‘resting’ Tregs). 
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Fig. 5 SLE patients had reduced CD25 surface densities on Tregs. CD25 surface 
densities on CD4+Foxp3+ Tregs were compared between ivIg-treated SLE patients and 
healthy blood donors (controls), considering all time points where CD25 quantification 
was available. The insert shows the P-value obtained by a distribution-independent 
Mann-Whitney test. 
 
Fig. 6 Correlations between average CD25 surface density on Foxp3+ Tregs and Vβ11 
and Vβ14 average perturbations in patients under ivIg treatment. Each dot represents a 
patient and is annotated with the corresponding patient-code. Inserts indicate Spearman 
rank correlation coefficients and corresponding p-values. 
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Fig S1 TCR CDR3 profiles of patient LI1 at various time points (analogously to Fig. 1) 
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Fig S2 
TCR CDR3 V!1 profiles in patient FA1 before and after 1st and 2nd ivIg infusions 
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Fig. S3 Individual pre-ivIg and post-ivIg CD25 MFI of Foxp3+ Tregs in relation to V!11 
and V!14 average perturbation under ivIg. For those patients where individual 
cytometric pre- and post-ivIg CD25 MFI measures were available, they are shown 
analogously to Fig. 6. Filled circles indicate pre-ivIg, triangles post-ivIg measures and 
open circles averages as shown in Fig. 6, on which also the regression line was 
calculated. *For LI1 and F2, pre-ivIg values represent the time before initiation of the 
respective second ivIg cycle of these patients. 
